
Ozette: Seattle AI Profile — Product, Footprint & Verified Record

Verified: November 19, 2026 · Canonical URL: https://tygartmedia.com/ozette-seattle-wa-ai-profile/

Verified Record Summary: As of November 19, 2026, Ozette Technologies operates as an independent, privately held Seattle computational immunology company with 28 employees listed on the Fall 2026 GeekWire 200. Spun out of Fred Hutchinson Cancer Center in 2020 and incubated at AI2, the company builds the Resolve Analysis Platform, an Ozette MCP server for agentic cross-study querying, and lab/managed cytometry services for research use. Total disclosed venture funding stands at $32M across its Seed and $26M Series A rounds led by Madrona Venture Group.



Field	Verified Record (As of Nov 19, 2026)
Company	Ozette (Ozette Technologies)
Official Website	https://www.ozette.com/
Washington HQ	Seattle, WA (exact street address not listed on homepage footer)
Other WA Footprint	Spun out of Seattle's Fred Hutchinson Cancer Center and incubated at Allen Institute for AI (AI2 Incubator / AI House); local partnerships with Bloodworks Northwest, Umoja Biopharma, and Fred Hutch's CITN
Founded	2020 (Fred Hutch / AI2 spinout; GeekWire 200 Fall 2026 lists 2021)
Founders / Leadership	Dr. Greg Finak (Co-Founder & CEO), Dr. Raphael Gottardo (Co-Founder), Evan Greene (Co-Founder), Ali Ansary (Co-Founder & Former CEO)
Stage	Series A
Announced Funding	$32M ($6M Seed in late 2020/early 2021 + $26M Series A in July 2022)
Team Size	28 (GeekWire 200, Fall 2026)
Primary Ecosystem Ties	Fred Hutchinson Cancer Center spinout, AI2 Incubator (AI House) alumnus, Madrona / M12 / Cercano / AI2 / Fred Hutch (investors), Bloodworks Northwest & Umoja Biopharma partnerships, GeekWire 200

What Ozette Builds

Ozette Technologies builds the Resolve Analysis Platform, an AI- and computationally-driven flow and spectral cytometry software suite that replaces subjective manual gating with 1-click, control-traceable single-cell immune phenotyping across studies and laboratory sites. As noted in the footer of the Ozette official website, its tools are built strictly for research use only and are not intended for clinical diagnostic use.

Alongside self-serve software documented on the Ozette Pricing page—including a 7-day, 60-file trial and academic plans starting at $35/month billed annually—Ozette provides an Ozette MCP server that allows scientists to connect their own AI assistants to query and compare standardized, phenotyped immune cell populations across multiple clinical and preclinical studies. The company complements software with Ozette Lab (assay data generation) and Managed Cytometry Analysis services.

Washington Footprint and Leadership

Ozette's origins sit squarely at the intersection of Seattle's biomedical and AI research institutions. The company spun out of Seattle's Fred Hutchinson Cancer Center in 2020 and was incubated at the Allen Institute for Artificial Intelligence (AI2 Incubator / AI House), where it continues to appear as an active, unacquired portfolio company on the AI House companies directory. While the GeekWire 200 lists a 2021 founding year (aligned with its early 2021 seed announcement) and 28 employees in Seattle, GeekWire spinout coverage dates the Fred Hutch and AI2 spinout to 2020.

Ozette was co-founded by Dr. Greg Finak, Dr. Raphael Gottardo, Evan Greene, and Ali Ansary, as documented on the Ozette About page. Following a leadership transition, co-founder Dr. Greg Finak—a veteran computational cytometry and single-cell methods researcher and former Senior Scientist at Fred Hutchinson Cancer Center who previously served as CTO—now leads the company as CEO, succeeding co-founder and founding CEO Ali Ansary (an attending physician at UW Medicine and former AI2 Incubator Entrepreneur-in-Residence). Co-founders Dr. Raphael Gottardo (subsequently at Lausanne University) and Evan Greene also came from Fred Hutch.

Products, Users, and Public Traction

Ozette serves pharmaceutical and biotech clinical trial sponsors, contract research organizations (CROs), academic research centers, and flow cytometry core facilities seeking consistent cross-study immune profiling. In April 2026, Ozette expanded its global clinical-trial footprint through a strategic partnership with Cerba Research, pairing Cerba's global clinical-trial laboratory network with Ozette's 48-color spectral flow cytometry pan-immune profiling assay and AI analytics platform.

That global CRO collaboration builds on an established base of Pacific Northwest life sciences partnerships. Earlier announced collaborators include Bloodworks Northwest / Bloodworks Bio (September 2023 cell-therapy partnership), Seattle-based Umoja Biopharma (July 2023 preclinical oncology partnership), and the Cancer Immunotherapy Trials Network (CITN) headquartered at Fred Hutchinson Cancer Center.

Funding, Stage, and Place in Washington's AI Landscape

Ozette has raised $32M in total disclosed venture capital across two rounds led by Seattle's Madrona Venture Group: a $6M seed round (late 2020 / announced early 2021) and a $26M Series A in July 2022. Its investor roster spans major Pacific Northwest and life sciences institutions, including Madrona Venture Group, M12 (Microsoft's venture fund), Cercano Management (formerly Vulcan Capital), Allen Institute for Artificial Intelligence (AI2), Alexandria Venture Investments, Ascent Capital Advisors, Duke University, Fred Hutchinson Cancer Center, and OCV Partners.

Within Washington's AI ecosystem, Ozette is a flagship bridge between Seattle's South Lake Union biotech cluster and its AI research institutions. Combining Fred Hutch immunology, AI2 incubation, Microsoft and Madrona capital, and recent clinical-trial commercialization with Cerba Research, the company demonstrates how domain-specific computational biology startups in Washington are pairing standardized assays with modern MCP-connected analytics.

Verified Primary Sources & Official References

• Ozette Official Website: https://www.ozette.com/
• Ozette About Page: https://www.ozette.com/about.html
• AI House / AI2 Incubator Companies: https://aihouse.vc/incubator/companies
• Cerba Research: https://www.cerbaresearch.com/
• GeekWire — Ozette $26M Series A Coverage: https://www.geekwire.com/2022/madrona-backed-biotech-startup-ozette-lands-26-million-for-immune-cell-tech/
• GeekWire 200: https://www.geekwire.com/geekwire-200/

Companion Markdown twin: https://tygartmedia.com/wp-content/uploads/2026/11/ozette-seattle-wa-ai-profile.md (also mirrored at https://tygartmedia.com/ozette-seattle-wa-ai-profile.md). Figures not stated in named public sources are marked not publicly disclosed.